Illumina vs Natera

Illumina and Natera are two prominent players in the genomics industry, each offering unique strengths and opportunities for investors. Illumina, a leader in DNA sequencing technology, has shown consistent growth and innovation. Natera, on the other hand, focuses on genetic testing services, particularly in the field of reproductive health. Both companies have experienced fluctuations in their stock prices, influenced by market trends and company developments. Investors should carefully consider the potential risks and rewards of investing in these stocks.

Illumina or Natera?

When comparing Illumina and Natera, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Illumina and Natera.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Illumina has a dividend yield of -%, while Natera has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Illumina reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Natera reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Illumina P/E ratio at -7.71 and Natera's P/E ratio at -54.25. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Illumina P/B ratio is 16.34 while Natera's P/B ratio is 18.95.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Illumina has seen a 5-year revenue growth of 0.26%, while Natera's is 1.11%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Illumina's ROE at -64.72% and Natera's ROE at -36.74%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $145.58 for Illumina and $128.07 for Natera. Over the past year, Illumina's prices ranged from $86.58 to $151.37, with a yearly change of 74.84%. Natera's prices fluctuated between $36.90 and $133.54, with a yearly change of 261.89%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.